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Abstract
Summary The aim of this study was to determine the total
medical costs for treating displaced femoral neck fractures
with hemi- or total hip arthroplasty in fit elderly patients.
The mean total costs per patient at 2 years of follow-up were
€26,399. These results contribute to cost awareness.
Introduction The absolute number of hip fractures is rising
and increases the already significant burden on society. The
aim of this study was to determine the mean total medical
costs per patient for treating displaced femoral neck fractures
with hemi- or total hip arthroplasty in fit elderly patients.
Methods The population was the Dutch sample of an interna-
tional randomized controlled trial consisting of femoral neck
fracture patients treated with hemi- or total hip arthroplasty.
Patient data and health care utilization were prospectively col-
lected during a total follow-up period of 2 years. Costs were
separated into costs for hospital care during primary stay, hos-
pital costs for clinical follow-up, and costs generated outside
the hospital during rehabilitation. Multiple imputations were
used to account for missing data.
Results Data of 141 participants (mean age 81 years) were
included in the analysis. The 2-year mortality rate was 19 %.
The mean total cost per patient after 10 weeks of follow-up
was €15,216. After 1 and 2 years of follow-up the mean total
costs were €23,869 and €26,399, respectively. Rehabilitation
was the main cost determinant, and accounted for 46 % of
total costs. Primary hospital admission days accounted for
22 % of the total costs, index surgery for 11 %, and physical
therapy for 7 %.
Conclusions Themain cost determinants for hemi- or total hip
arthroplasty after treatment of displaced femoral neck frac-
tures (€26,399 per patient until 2 years) were rehabilitation
and nursing homes. Most of the costs were made in the first
year. Reducing costs after hip fracture surgery should focus on
improving the duration and efficiency of the rehabilitation
phase.
Keywords Arthroplasty . Cost analysis . Femoral neck
fracture . Hip fracture . Medical costs
Introduction
The major complication of osteoporosis is the clinical mani-
festation of a hip fracture. Based upon global trends and de-
mographic changes the worldwide number of hip fractures is
expected to be over 7.3 million patients in the year 2050 [1, 2].
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In The Netherlands the number of patients sustaining a hip
fracture has more than doubled since 1981 to almost 19,000
patients in 2012 [3]. Almost 60 % of all proximal femoral
fractures concern the femoral neck and 80% of these fractures
are displaced [4]. The Garden classification is frequently used
for describing femoral neck fractures in the elderly [5]. Garden
type 3 and 4 represent displaced fractures. Femoral neck frac-
tures can be treated using a non-operative approach, internal
fixation, or arthroplasty. The arthroplasty group includes
hemiarthroplasty and total hip arthroplasty. Approximately
62 % of patients aged 65 years or older are primarily treated
with arthroplasty; hemiarthroplasty is performed in this group
in 78 % of patients on average [6]. Different insights into the
preferred treatment of femoral neck fractures are the subject of
ongoing international debate [7]. An international survey re-
vealed that 75 % of the responding surgeons prefer primary
arthroplasty for patients over 60 years of age with a displaced
fracture. For patients under 60 years of age with a displaced
fracture (Garden type 3 or 4), hemiarthroplasty was preferred
by 11 % and 25 % of respondents, respectively [7]. Although
initial costs for arthroplasty are higher than for internal fixa-
tion, arthroplasty has been proven to be a cost-effective ther-
apy [8–11].
According to data of the Dutch Ministry of Health, Welfare
and Sports, hip fracture-associated crude total cost in
The Netherlands was €471.5 million in 2011 [12]. Insight into
health care use and associated costs is gaining importance as
the burden of health care costs threatens to exceed the finan-
cial resources available. Such insight may reveal options for
cutting down health care expenses. Although surgeons are
expected to have a general idea about the costs for treatments
they provide, these data are not easily available [13–15]. Re-
cently, data became available on the total medical costs of
femoral neck fracture patients treated with internal fixation
in The Netherlands [16]. To the best of our knowledge, de-
tailed analysis of the costs of hemi- or total hip arthroplasty for
femoral neck fractures in The Netherlands has not been pub-
lished before. Therefore, the aim of this study was to provide a
detailed overview of the costs consumed by patients with a
displaced femoral neck fracture that was treated with hemi- or
total hip arthroplasty.
Patients and methods
This cost study was conducted as a cohort study alongside the
Dutch sample of the HEALTH trial (hip fracture evaluation
with alternatives of total hip arthroplasty versus
hemiarthroplasty, NCT00556842), an international random-
ized controlled trial comparing total hip arthroplasty and
hemiarthroplasty on revision surgery and quality of life in
patients with a displaced femoral neck fracture. The local
medical research ethics committees of all participating centers
approved the study. Informed consent was obtained from all
individual participants included in the study.
Population
In The Netherlands, 14 hospitals participated and enrolled 150
patients between December 15, 2008 and February 14, 2011.
Patients were eligible if they: (1) were adults aged ≥50 years,
(2) had a (radiologically confirmed) displaced femoral neck
fracture (ICD-10 code S72.0; Garden type 3 and 4) after a low
energy impact and no other major trauma, (3) were operated
within 3 days of presenting to the emergency room, and (4)
were ambulatory pre-fracture (with or without aid). Patients
provided informed consent. Patients were excluded if they: (1)
were not suitable for treatment with arthroplasty (i.e., inflam-
matory arthritis, rheumatoid arthritis, pathologic fracture, or
severe osteoarthritis of the hip), (2) had infection or retained
hardware around the affected hip, (3) had a bone metabolism
disorder other than osteoporosis, (4) were moderately or se-
verely cognitively impaired pre-fracture, (5) had dementia or
Parkinson’s disease severe enough to compromise the rehabil-
itation process, or (6) were not likely to be able to complete
follow-up.
Treatment and follow-up
Medical optimization was warranted for all included patients
before surgery. Within 72 h after presenting to the emergency
department, patients were treated with hemi- or total hip
arthroplasty. The exact treatment including material choice
(cemented or uncemented and unipolar or bipolar prosthesis)
was left to the treating surgeon. Antibiotic prophylaxis and
thromboprophylaxis were prescribed to all patients according
to local protocols. Post-operative weight bearing was as toler-
ated and early mobilization was encouraged. All patients were
screened and treated for osteoporosis if deemed necessary.
Follow-up measurements were performed at 10 weeks and at
6, 9, 12, 18, and 24 months after the primary surgery.
Cost measurement
This study included the following categories for hip-related
costs: (1) hospital costs during primary hospital stay, including
emergency department visit, diagnostic evaluations, surgery,
and admission days; (2) hospital costs during follow-up, in-
cluding diagnostic evaluations, outpatient clinic visits, diag-
nosis and treatment of adverse events, revision surgery, and
admission days; and (3) non-hospital costs of rehabilitation
and aids.
Data on health care use were collected prospectively at
each scheduled follow-up contact and at the close-out visit at
the end of the study. Data were collected from the study case
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report forms (items are listed in electronic supplementary ma-
terial (ESM) Supplemental Table 1) and from the patient’s hos-
pital file. At each follow-up contact, patients were asked to
complete a questionnaire on their health care use. This ques-
tionnaire was a customized version of the BTrimbos and iMTA
questionnaire on Costs associated with Psychiatric illness^
(Tic-P), which has been validated for use in health care cost
studies [16, 17]. An English version of the TicP questionnaire is
available online [18]. The questionnaire included questions on
stay in a hospital, rehabilitation center or nursing facility, num-
ber of contacts with an intramural medical specialist or para-
medical worker during admission and follow-up, medication
use, comorbidity and use of walking aids. Missing data were
collected during the close-out visit at each hospital.
The total number of consumption units per cost category
was multiplied by the unit prices. All unit prices were indexed
with the national consumer price index to 2012 and are pre-
sented in Table 1. Costs for the index surgery, including time
spent in the operating room, theater personnel, overhead, an-
esthesia, and implant material and general equipment, was
provided by two teaching hospitals and one academic hospi-
tal. Data from the teaching hospitals were averaged in order to
obtain a realistic estimate of the average prices in the partici-
pating teaching hospitals. Reference cost prices of most other
health care resources were derived from the Dutch manual on
cost research, methods and standard costs in economic health
care evaluations [19]. The NZa (Nederlandse Zorgautoriteit;
Dutch Health care Authority) is the Dutch market regulator in
care and advises the Minister on health care costs. This insti-
tute provided the unit prices for intramural diagnostic proce-
dures. Costs of medication were derived from the CVZ (Col-
lege voor zorgverzekeringen; Health Care Insurance Board),
which is online accessible on www.medicijnkosten.nl. Costs
of rehabilitation aids were obtained from a local home care
firm that is a representation of national practice. Costs of aids
were calculated according to the annuity method, applying an
interest rate of 4.5 % and a 10-year write-off period. With over
90 % of the patients in the study being retired, the costs for
production losses were considered of limited importance for
this population, and were thus excluded. Home care was also
excluded, since it was impossible to determine which propor-
tion of the total home care received was due to the hip fracture.
As done previously in a similar study on internal fixation of
femoral neck fractures, costs of osteoporosis screening were
included in radiology/diagnostic studies costs, costs of visits
to an osteoporosis specialist were included in outpatient
clinic-visit costs, and costs for osteoporosis treatment were
included in medication costs.
Statistical analysis
Data were analyzed using SPSS (version 20.0, SPSS Inc.,
Chicago, IL, USA). Replacement of missing values for cost
items was done with multiple imputations following the pre-
dictive mean matching method, using ten imputations [20].
The following variables were included in the imputation mod-
el: sex, age, ASA at baseline, walking independently at base-
line, treatment, costs of initial surgery, and all other cost cat-
egories at 10 weeks and at 6, 9, 12, 18, and 24months. Each of
the ten complete datasets were further analyzed by non-
parametric bootstrapping using 1000 bootstraps per dataset
[21]. The 95 % confidence interval around the mean costs
was determined by taking the 2.5th and the 97.5th percentile
of these bootstrap replications. Costs were calculated for the
total study population.
Results
Demographics
The 14 participating hospitals registered 592 consecutive pa-
tients with a femoral neck fracture, of whom 181 were eligible
and 150 (25 %) subsequently gave informed consent (Fig. 1).
One patient withdrew consent immediately, one patient died
before surgery, and seven patients were treated with internal
fixation rather than arthroplasty. A total of 141 patients
remained for the current cost analysis, of whom 74 were treat-
ed with hemiarthroplasty and 67 with a total hip arthroplasty.
The mean age was 81 (SD 7; range 57–100) years, 2 patients
(1%; both females) were younger than 60 years of age. A total
of 96 patients (68 %) were female. The mean age was 80 (SD
8; range 57–100) years for females and 81 (SD 6; range 69–
91) years for males. No patients (0%) hadASA class 1 or class
5, 67 (48%) patients had ASA class 2, 72 (51%) ASA class 3,
and 2 (1 %) ASA class 4. A total of 136 (97 %) patients were
not institutionalized before the fracture, and 102 (72 %) pa-
tients were independently ambulatory before the fracture.
Clinical outcome and health care consumption
The mean duration of hospital admission was 10 days (SD 8).
One patient with a complicated clinical course was discharged
at 90 days after the initial surgery. Within 14 days after sur-
gery, 87 % (N=123) of the patients were discharged. The
discharge destination was a rehabilitation or nursing facility
in 56 % of patients, and 44 % of patients went to their own
house. Median stay per patient was 10 days (SD 28) in a
rehabilitation facility, 14 days (SD 42) in a nursing facility,
and 18 days (SD 62) in an elderly home. During rehabilitation,
patients had a mean of 52 (SD 5) physical therapy sessions per
patient.
A total of 118 adverse events (AEs) occurred; 77 patients
(55 %) had no AE at all. The most frequent AEs were a
subsequent fracture (N=19; 13 %), a superficial wound infec-
tion (N=11; 8 %), and dislocations (N=10; 7 %). Less than
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Table 1 Sources and unit costs of health care resources
Cost categories Unit Source of consumption data Source of value Unit price (€)
Hospital costs—primary stay
Emergency department visit Visit Hospital registry Cost manuala 160.34
Radiology/diagnostic modalities
X-ray X-ray Hospital registry NZab 54.14
CT-scan pelvis CT-scan Hospital registry NZab 238.25
MRI scan pelvis MRI scan Hospital registry NZab 274.16
Ultrasound Ultrasound Hospital registry NZab 86.07
DEXA scan DEXA scan Hospital registry NZab 114.52
Skeletal scintigraphy Scintigraphy Hospital registry NZab 194.37
Surgery
Surgeon Hour Study registry (CRF) Cost manuala 143.88c/109.37d
Operating roome Hour Study registry (CRF) Hospital/industry dataf 738.60c/885.00d
Equipment and implant
Cemented hemiarthroplasty Operation Study registry (CRF) Hospital/industry dataf 1362.00c/1197.73d
Cemented total hip arthroplasty Operation Study registry (CRF) Hospital/industry dataf 1465.75c/1684.45d
Uncemented total hip arthroplasty Operation Study registry (CRF) Hospital/industry dataf NA/2041.80d
Admission days Day Study registry (CRF) Cost manuala 610.57c/461.91d
Hospital costs—follow-up
Radiology/diagnostic modalities As described above
Outpatient clinic visits Visit Hospital registry + questionnaireg Cost manuala 136.98c/67.96d
Adverse events
Medicationh Dose per day Hospital registry/questionnaireg CVZi Variable
Emergency Visit Hospital registry Cost manuala 160.34
Brace Piece Hospital registry/questionnaireg Hospital/industry dataf 440.39
Admission days Day Study registry (CRF) Cost manuala 610.57c/461.91d
Revision surgery
Surgeon Hour Study registry (CRF) Cost manuala 143.88c/109.37d
Operating roome Hour Study registry (CRF) Hospital/industry dataf 738.60c/885.00d
Equipment and implant
Cemented hemiarthroplasty Operations Study registry (CRF) Hospital/industry dataf 1362.00c/1197.73d
Cemented total hip arthroplasty Operations Study registry (CRF) Hospital/industry dataf 1465.75c/1684.45d
Uncemented total hip arthroplasty Operations Study registry (CRF) Hospital/industry dataf NA/2041.80d
Cup revision Operations Study registry (CRF) Hospital/industry dataf 773.09
Open fenestration/bursectomy Operations Study registry (CRF) Hospital/industry dataf 524.20
Open reduction (OR) Operations Study registry (CRF) Hospital/industry dataf 333.96
Closed reduction (ER) Operations Study registry (CRF) Hospital/industry dataf 160.34
Antibiotic beads Operations Study registry (CRF) Hospital/industry dataf 324.83
Admission days Days Study registry (CRF) Hospital/industry dataf 610.57c/461.91d
Medicationj Dose per day Hospital registry/questionnaireg CVZi NA
Costs related to rehabilitation/changes in living situation
Rehabilitation center/nursing home
Elderly home Days Patient questionnaireg Cost manuala 95.57
Nursing home Days Patient questionnaireg Cost manuala 252.73
Rehabilitation clinic Days Patient questionnaireg Cost manuala 361.04
Home nursing day Days Patient questionnaireg Cost manuala 46.72
Physical therapy (outpatient) Hour Patient questionnaireg Cost manuala
Physical therapy Session Patient questionnaireg Cost manuala 38.23
Use of aids
Crutches Day Patient questionnaireg Home care firmk 0.07
Walker Day Patient questionnaireg Home care firmk 0.08–0.15
Wheelchair Day Patient questionnaireg Home care firmk 0.27
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ten patients had other AEs including pulmonary embolism,
myocardial infarction, cerebral vascular accident, pneumonia,
urinary tract infection, delirium, or decubitus. Eighteen revi-
sion surgeries were performed in ten patients (Table 2).
Table 1 (continued)
Cost categories Unit Source of consumption data Source of value Unit price (€)
Electric scooter Day Patient questionnaireg Home care firmk 0.70
Extra bed Day Patient questionnaireg Home care firmk 1.22
Extra toilet facilities Day Patient questionnaireg Home care firmk 0.10–0.20
Extra shower facilities Day Patient questionnaireg Home care firmk 0.10–0.18
Reference unit costs anno 2012 were used, or costs were adjusted to 2012 costs by using the national consumer price index
NA not applicable
a Cost manual—manual on cost research, methods and standard costs in economic health care evaluations, version 2010 [16]
b NZa; Nederlandse Zorgautoriteit (Dutch Health care Authority) standard costs
c Academic hospital
d General hospital
e Including operating room personnel, anesthesia, and overhead costs
f Hospital/industry data; costs were requested from one academic hospital, three regional hospitals, and one surgical equipment and implant firm. Means
were calculated and used as an estimation of the real costs in all participating sites
g Patient questionnaire—customized version of the BTrimbos and iMTA questionnaire on costs associated with psychiatric illness^ [17]
hMainly antibiotics and in-hospital thrombosis profylaxis
i CVZ—standard prices were used as described by the CVZ (College voor zorgverzekeringen; Health Care Insurance Board), online available on www.
medicijnkosten.nl
j Hip fracture-related medication only (i.e., pain medication and anti-osteoporosis medication; see ESM Supplemental Table 2 for details)
k Home care firm; costs of aids were requested from a home care firm and costs per day were calculated based on the calculated daily annuity. These costs
were used as an estimation of the real costs in all participating patients
Analyzed 
Assessed for eligibility (N= 592) Excluded  (N= 411)* 
Not meeting inclusion criteria : 
♦ < 50 years of age (N= 12) 
♦ Femoral neck fracture not confirmed (N= 2) 
♦ No displaced fracture not repairable with internal 
fixation (N= 76) 
♦ Not likely to be treated < 72 hours (N= 28) 
♦ Not ambulant prefracture (N= 8) 
♦ No medical optimization before surgery (N= 4) 
♦ High energy trauma (N= 1) 
♦ Other major trauma (N= 2) 
♦ No expertise present for total hip as well as 
hemiarthroplasty (N= 2) 
Meeting exclusion criteria 
♦ Not suitable for arthroplasty (N= 16) 
♦ Additional major trauma (N= 3) 
♦ Infection around the hip (N= 2) 
♦ Bone metabolism disease (N= 5) 
♦ Dementia (N= 158) 
♦ Parkinson (N= 76) 
♦ Likely follow-up problems (N= 173) 
♦ Enrolled in other study (N= 3) 
♦ Other reason (N= 38) 
N=141 
 Received hemi- or total hip arthroplasty (N= 141) 
••Treated with internal fixation (N= 7) 
♦ Dead before surgery (N= 1) 
♦ Immediate withdrawal informed consent (N= 1) 
Invited to participate (N= 181) 
Enrolled (N= 150) 
Fig. 1 Flow-chart of patient
enrollment process.
*Patients could meet more
than one exclusion criterion
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Dislocation was treated ten times; seven closed reductions
were done in the emergency department, two in the operating
room. One patient underwent an open reduction. Three con-
versions from hemiarthroplasty to total hip arthroplasty were
performed. One patient suffered three dislocations after the
conversion. One patient underwent an arthrotomy and joint
lavage three times to treat a deep infection. One periprosthetic
fracture was treated with plating. The 10-week mortality was
5 % (N=7), the 1-year mortality was 11 % (N=16), and the 2-
year mortality was 19 % (N=27). Patients died mainly due to
cancer (N=9), cardiovascular diseases (N=6), neurological
diseases (N=3), and the bone cement implantation syndrome
(N=2). The mean duration of follow-up was 22months (SD 9).
Costs
ESMSupplemental Table 3 shows the fraction of patients who
used health care and the volume of health care use per user.
These data were not imputed. Table 3 shows the calculated
mean costs for used health care after multiple imputations of
the missing data. The overall percentage of missing data was
17.8 % and the relative efficiency of the multiple imputations
was 0.98. In the first 10 weeks after the fracture the mean total
costs was €15,216, which was 58 % of the total costs. The
most important cost category was primary hospital stay ac-
counting for €9026. From this category, costs were predomi-
nantly related to hospital admission (€5732) and index surgery
(€2915). Other important costs were incurred for rehabilitation
facilities and nursing homes (€4707).
At 1 year of follow-up, the mean total costs per patient was
€23,869 (95 % CI €19,157–€30,136), this was 90 % of the
overall total costs. Fifty-five percent of costs were spent on
rehabilitation and changes in living situation with a total
amount of €13,138. Rehabilitation centers/nursing homes
(€11,694) and physical therapy at the outpatient clinic
(€1340) were the main cost determinants. After 2 years of
follow-up, the total rehabilitation-related costs (€14,429) still
accounted for 55 % of the total costs. The hospital costs for
follow-up almost doubled from €1705 (7 % of the total costs)
after 1 year to €2943 (11 %) after 2 years of follow-up. The
main items were costs related to adverse events which in-
creased by 181 % from €581 to €1052 and a 204 % increase
in costs for revision surgery from €480 to €980 (Fig. 2).
Discussion
The mean total costs per patient after treatment with hemi- or
total hip arthroplasty for femoral neck fracture were €23,869
(95 % CI €19,157–€30,136) at 1 year and €26,399 (95 % CI
€21,101–€33,213) at 2 years after a fracture.
These costs are in line with the range of €12,952 to €43,671
(as adjusted to 2012) found in literature [8–10, 22–27]. This
broad range can be explained by different variables used in the
studies. All studies were performed in western countries, but
with different health care systems, mean length of hospital
stay, reference costs, and rehabilitation facilities. The popula-
tions studied had a relatively small sample size ranging from
32 to 180 patients. One study, involving 19,808 patients, used
a Markov decision model [22]. Although most of the costs are
generated in the first year, the two studies with the lowest costs
had a follow-up of 1 year [23, 25], not taking into consider-
ation the late and costly complications. One study [9] did not
include treatment with hemiarthroplasty and two studies only
reviewed the costs for patients treated with hemiarthroplasty
[23, 24]. Also, previous studies used different types of costs
e.g., in-hospital costs only [8], the included populations dif-
fered in age, or included only women [25]. Results of the
current study correspond best with the results of the two larg-
est studies (adjusted costs €29,834 and €29,807, respectively),
both including both types of arthroplasty [10, 22].
In addition, from a prospective cohort study of 10,275
Dutch persons, the estimated incremental costs of medical
care were $9540 (adjusted to € in 2012: €11,715) in the first
Table 2 List of revision surgeries performed
Revision surgery 1 Revision surgery 2 Revision surgery 3 Revision surgery 4
Patient 1 Conversion to THA Closed reduction ED Closed reduction ED Closed reduction ED
Patient 2 Arthrotomy and joint lavage Arthrotomy and joint lavage Arthrotomy and joint lavage
Patient 3 Closed reduction ED Closed reduction ED Plate fixation periprosthetic frx
Patient 4 Closed reduction OR Closed reduction ED
Patient 5 Conversion to THA
Patient 6 Open reduction
Patient 7 Closed reduction ED
Patient 8 Arthrotomy
Patient 9 Conversion to THA
Patient 10 Closed reduction OR
THA, total hip arthroplasty; ED, emergency department; OR, operating room
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year after a hip fracture and $1017 (€1248) in the subsequent
year [28]. These incremental costs are comparable with the
€14,844 (first year) and €2529 (subsequent year) found in
the current study. De Laet et al. [28] found higher costs, but
that study did not include detailed costs of adverse events,
revision surgeries, and costs of diagnostic modalities. The
Table 3 Mean costs of femoral neck fracture patients treated with hemi- or total hip arthroplasty (N= 141)
Cost categories Cost until 10 weeks (€) Costs until 1 year (€) Costs until 2 years (€)
A) Hospital costs—primary stay
Emergency department visit 160 (160–160) 160 (160–160) 160 (160–160)
Radiology/diagnostic modalities 219 (206–232) 219 (206–232) 219 (206–232)
Surgery 2,915 (2,798–3,023) 2,915 (2,798–3,023) 2,915 (2,798–3,023)
Admission days 5,732 (4,452–7,966) 5,732 (4.452–7,966) 5,732 (4,452–7,966)
Total 9,026 (7,706–11,295) 9,026 (7,706–11,295) 9,026 (7,706–11,295)
B) Hospital costs—follow-up
Radiology/diagnostic modalities 115 (103–128) 240 (212–270) 344 (278–427)
Outpatient clinic visits 120 (109–133) 297 (263–336) 416 (355–494)
Adverse events 200 (66–392) 581 (280–1,056) 1,052 (568–1,781)
Revision surgery 396 (61–990) 480 (112–1,100) 980 (345–1,940)
Medication 82 (74–92) 106 (93–121) 151 (125–182)
Total 914 (499–1,541) 1,705 (1,102–2,563) 2,943 (1,894–4,308)
C) Costs related to rehabilitation/changes in living situation
Rehabilitation center/nursing home 4,707 (3,627–5,874) 11,694 (8,132–16,350) 12,240 (8,542–17,008)
Physical therapy (outpatient) 549 (470–640) 1,340 (1,162–1,537) 1,975 (1,627–2,370)
Use of aids 20 (17–25) 105 (78–139) 214 (166–270)
Total 5,276 (4,200–6,467) 13,138 (9,486–17,956) 14,429 (10,461–19,552)
D) Total costs 15,216 (13,051–18,323) 23,869 (19,157–30,136) 26,399 (21,101–33,213)
Costs are presented as mean costs at each follow-up moment with 95 % uncertainty interval between brackets
The data have been imputed. If a patient had not consumed health care, costs for that item were recorded as €0
Fig. 2 Relative contribution of costs categories to the total treatment costs of patients until 2 years of follow-up
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in-depth method of our study can be considered more specific
as the total costs are presented in more detail.
Recently, a similar study was published involving Dutch
elderly patients with a femoral neck fracture (50 years or older)
who were primarily treated with internal fixation [16]. Both
studies had the same design and used identical research
methods, questionnaires, statistics, and resources, making it
suitable for direct comparison. After two years of follow-up
the costs, adjusted to 2012 for the total internal fixation group
were €20,368 (original data: €19,425; 95 % CI €5,237–€58,
874). The relative contributions of the different cost categories
were very comparable with respect to rehabilitation (46 % of
total costs for arthroplasty and 49 % for internal fixation) and
hospital admission days (both 22 %), with higher absolute
costs in the current arthroplasty study. These differences can
be explained by the generally older population in the
arthroplasty group based on baseline characteristics. In the
current study, the mean age was 10 years older (81 versus
71), patients were more often ASA 3–4 (54 versus 13 %), used
aids pre-fracture more often (28 versus 13 %), and had a
displaced fracture more often (100 versus 46 %). It is likely
that older patients are admitted to a rehabilitation facility more
often longer. Moreover, the mean number of hospital admis-
sion days (10 versus 7 days) was longer in the arthroplasty
group. Subgroup analysis of 67 patients (27%)who underwent
revision to arthroplasty after primary internal fixation resulted
in adjusted costs of: €28,031 (€26,733; 95 % CI €9465–€80,
029), which exceeds the costs of primary arthroplasty. This
emphasizes the need to carefully select primary treatment for
hip fractures as conversion from internal fixation to
arthroplasty is even more costly than primary arthroplasty.
This study had some limitations. First, the population has
been selected, based upon the eligibility for arthroplasty.
Therefore it is a specific subset of the total population which
presented to the emergency department of the participating
hospitals. The patients were relatively healthy, fit, and most
were independent walkers before the fracture. Patients with
dementia or Parkinson’s disease were excluded, but these pa-
tients represent a substantial part of the general hip fracture
population. These patients may have complex needs and incur
higher costs, consequently leading to an underestimation of
the mean costs presented. Costs are based on Dutch prices and
may vary depending on the health care system used. However,
by comparing with published costs from other Western coun-
tries, we showed that the results are applicable to other settings
as well. Secondly, the actual costs are expected to be even
higher as costs for pre-hospital care, costs for routine blood
analysis at the emergency department and wards, and periop-
erative consultation by other medical specialists and, although
not routinely applied, forensic autopsy were not included. On
the other hand, the number of visits for follow-up and X-rays
are lower in general practice than in a trial setting. Also, the
amounts used in the cost price manuals used may differ from
the actual costs. However, these costs are not expected to be
substantial. Finally, costs for home care and general practition-
er (GP) visits were not included as for most patients it was
impossible to discriminate which part of the post-fracture
home care and GP visits was actually due to the hip fracture
and not due to care for other pre- or post-fracture conditions.
With these limitations in mind the results of the current study
are in line with previous international publications.
In conclusion, the treatment of displaced femoral neck frac-
tures with hemi- or total hip arthroplasty is costly with mean
total costs after one year of €23,869 and €26,399 after 2 years
of follow-up. Rehabilitation and nursing homes account for
almost half of the total medical costs, revision surgery, and
adverse events not even 10 %. Focus on improvements of the
rehabilitation phase can result in reducing costs.
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